期刊文献+

45例多发性骨髓瘤患者细胞免疫功能变化及其临床意义 被引量:7

Cellular immune function and its clinical implications in 45 patients with multiple myeloma
原文传递
导出
摘要 目的 探讨多发性骨髓瘤(MM)患者细胞免疫功能变化及其临床意义.方法 45例MM患者分为初诊组(18例)、治疗后病情稳定期组(17例)和复发/难治组(10例),以20名健康志愿者为正常对照组.采用流式细胞术检测外周血T细胞亚群、NK细胞、树突细胞(DC)、辅助性T细胞(Th1和Th2)、调节性T细胞(Treg)和Th17细胞在CD4+细胞中所占比率.结合患者血清β2微球蛋白(β2-MG)、LDH和HGB水平进行分析.结果 ①初诊组患者Treg、NK细胞比率及CD4+/CD8+细胞、DC1/DC2、Th1/Th2比值较正常对照组和病情稳定期组均降低,IL-17A/Treg比值显著升高(P值均<0.05);与病情稳定期组相比,复发/难治组患者CD4+/CD8+细胞、Th1/Th2比值显著下降,IL-17A/Treg比值显著升高(P值均<0.05).②随着临床ISS分期增高,CD4+/CD8+细胞、Th 1/Th2比值明显降低,IL-17A/Treg比值明显升高(P值均<0.05).③MM患者CD4+/CD8+细胞、Th 1/Th2、DC 1/DC2比值与血清β2-MG和LDH的表达水平呈显著负相关(P值均<0.05);IL-17A/Treg比值与两者呈显著正相关(P值均<0.05);各项免疫指标与HGB水平无明显相关性(P值均>0.05).结论 CD4+/CD8+细胞、Th 1/Th2、DC1/DC2以及IL-17A/Treg比值的异常与MM患者的病情分期、疗效、发展以及预后密切相关. Objective To investigate cellular immune function and its clinical significance in patients with multiple myeloma (MM).Methods 45 MM patients were divided into three groups:newly diagnosed (n=18),stable stage (n=17) and relapsed/refractory (n=10).The frequencies of T cell subtypes,natural killer (NK) cells,dendritic cells (DC),helper T cells (including Th1 and Th2),regulatory T cells (Treg) and Th17 cells in peripheral blood were detected by flow cytometry.Serum concentrations of β2 microglobulin (β2-MG),lactate dehydrogenase (LDH) and hemoglobin (Hb) were also detected,respectively.Results Compared with controls and stable stage group,the ratios of CD4+/CD8+,DC1/DC2,and Th1/Th2,the numbers of Treg and NK cells were significantly lower in newly diagnosed group.However,the ratio of IL-17A/Treg was significantly higher in newly diagnosed group (P〈0.05).Compared with stable stage group,the ratios of CD4+/CD8+,DC 1/DC2 and Th 1/Th2 were significantly lower,and the ratio of IL-17A/Treg was significantly higher in relapsed/refractory group (P〈0.05).In higher ISS stages,the ratios of CD4+/CD8+ and Th1/Th2 were significantly lower and the ratio of IL-17A/Treg was significantly higher (P〈0.05).There were negative correlations between the ratios of CD4 +/CD8 +,DC1/DC2,Th1/Th2 and the levels of β2-MG and LDH,respectively (P〈0.05).The ratio of IL-17A/Treg was positively correlated with the levels of β2-MG and LDH (P〈0.05).They were no correlated with the level of Hb (P〉0.05).Conclusion The abnormal ratios of CD4+/CD8+,DC1/DC2,Th1/Th2 and IL-17A/Treg were closely related with disease condition stages,treatment outcomes,progression and prognosis in MM patients.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第12期1053-1057,共5页 Chinese Journal of Hematology
基金 教育部博士点基金(20130001110090、20120001120132) 首都健康培育项目(z111107067311050)
关键词 多发性骨髓瘤 CD4-CD8比值 Th1-Th2平衡 树突细胞 白细胞介素17 Multiple myeloma CD4-CD8 ratio Th1-Th2 balance Dendritic cells
  • 相关文献

参考文献16

  • 1王琦侠,闫永平,吉兆华,倪庆仁,宋艳萍,李苏童,谢佳,任婧婧,郭亮,戴进前.多发性骨髓瘤患者的生活质量及相关因素研究[J].中华流行病学杂志,2013,34(12):1233-1236. 被引量:11
  • 2Pratt G, Goodyear O, Moss P, et al. Immtmodefieniency and immunotherapy in multiple myeloma [J]. Br J Haematol, 2007, 138(5): 563-579.
  • 3Rosenblatt J, Bar-Nataa M, Munshi NC, et al. Immunotherapyfor multiple myeloma [J]. Expert Rev Hematol, 2014, 7( 1 ): 91- 96.
  • 4Anderson KC, Alsina M, Bensinger W, et al. NCCN Clinical practice guidelines in oneology: multiple myeloma [J]. J Natl Compr Cane Netw, 2011, 7(9): 908-942.
  • 5Dude BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma [J]. Leukemia, 2006, 20(9): 1467-1473.
  • 6Borrello I. Can we change the disease biology of multiple myeloma? [J]. Leuk Res, 2012, 36 Suppl.1 :$3-12.
  • 7Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopa- thy of undetermined significance (MGUS) and smoldering (as- ymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management [J]. Leukemia, 2010, 24(6): 1121-1127.
  • 8Ogawara H, Hiroshi H, Tohru Y, et al. High Thl/Th2 ratio in patients with multiple myeloma [J]. Leuk Res, 2005, 29 (2): 135-140.
  • 9Jurisic V, Srdic T, Konjevic G, et al. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients [J]. Med Oncol, 2007, 24(3): 312-317.
  • 10Brown R, Murray A, Poper B, et al. Either interleukin- 12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma [J]. Br J Haematol, 2004, 125(6): 743-748.

二级参考文献35

  • 1姜宝法,刘春晓,崔永春,徐涛,徐敏,王家林,杜君.EORTCQLQ-C30的信度、效度研究[J].中国临床心理学杂志,2005,13(1):31-32. 被引量:120
  • 2万崇华,陈明清,张灿珍,汤学良,孟琼,张晓磬.癌症患者生命质量测定量表EORTC QLQ-C30中文版评介[J].实用肿瘤杂志,2005,20(4):353-355. 被引量:1270
  • 3邱录贵.多发性骨髓瘤的发病与国人特点[J].中国实用内科杂志:临床前沿版,2006,26(6):886-888. 被引量:52
  • 4Mahindra A, Laubach J, Raje N, et al. Latest advances and cur- rent challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol, 2012, 9:135-143.
  • 5Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest, 2012, 122: 3456-3463.
  • 6Muller YD, Seebach JD, Bfihler LH, et al. Transplantation tolerance: Clinical potential of regulatory T cells. Self Nonself, 2011, 2: 26-34.
  • 7Zou W, Restifo NP. T(H)17 cells in tumour immunity and immu- notherapy. Nat Rev Immunol, 2010, 10: 248-256.
  • 8Chi LJ, Lu HT, Li GL, et al. Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma. Clin Exp Immunol, 2010, 161: 480-489.
  • 9Chatila TA. Role of regulatory T cells in human diseases. J Allergy Clin Immunol, 2005, 116: 949-959.
  • 10Tesmer LA, Lundy SK, Sarkar S, et al. Thl7 cells in human disease. Immunol Rev, 2008, 223: 87-113.

共引文献19

同被引文献59

引证文献7

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部